CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.
April 19th 2025
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2
October 26th 2018After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.
Preventing Myelofibrosis from Progressing to Acute Myeloid Leukemia
September 28th 2018Diagnosing and treating the disease before it turns into AML is a key area of study, said Srdan Verstovsek, M.D., Ph.D., medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Relatives of Patients With Myeloid Blood Cancers May be at Two-Fold Risk for Disease
August 14th 2018Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.
Novel Drug Granted Priority Review for Acute Myeloid Leukemia Treatment
June 27th 2018The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.
Small Percentage With Myelofibrosis Develop Aggressive Lymphoma from JAK Inhibition
June 25th 2018While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.
Patients with MPNs Willing to Alter Diet, Supplement Use to Alleviate Symptoms
March 6th 2018Nutritional change may be a potential strategy to improve symptom burden and inflammation in patients with MPNs, whohave increased inflammatory cytokines, which contribute to symptoms such as fatigue, night sweats and bone pain, as well as low cholesterol and weight loss related to nutritional deficiencies.
Surviving Survivorship: A Chronic Illness
March 3rd 2018For more than 20 years, Barbara Abernathy, Ph.D., has been living with cancer and its aftermath. She was diagnosed with a rare type of blood cancer collectively known as myeloproliferative neoplasms (MPNs), which transitioned into acute myeloid leukemia. In 2013, she underwent a stem cell transplantation — a lifesaving gift from a young man in Germany.